Curis, Inc. (NASDAQ:CRIS)’s share price was down 5.4% during mid-day trading on Monday . The stock traded as low as $0.88 and last traded at $0.88. Approximately 2,101,400 shares changed hands during mid-day trading, an increase of 210% from the average daily volume of 677,276 shares. The stock had previously closed at $0.93.

Several equities analysts have recently issued reports on CRIS shares. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a research note on Monday, October 16th. Guggenheim started coverage on Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 price objective for the company. BidaskClub cut Curis from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Three investment analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $6.50.

The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.

Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The business had revenue of $2.44 million for the quarter, compared to analyst estimates of $2.19 million. During the same period last year, the business posted ($0.21) EPS. Curis’s revenue was up 38.6% on a year-over-year basis. equities research analysts forecast that Curis, Inc. will post -0.41 EPS for the current fiscal year.

In other Curis news, CEO Ali Ph.D. Fattaey bought 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average price of $1.06 per share, with a total value of $53,000.00. Following the transaction, the chief executive officer now owns 115,890 shares of the company’s stock, valued at $122,843.40. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 4.07% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRIS. Prudential Financial Inc. acquired a new position in Curis during the first quarter worth approximately $105,000. American International Group Inc. increased its position in Curis by 7.1% during the first quarter. American International Group Inc. now owns 68,733 shares of the biotechnology company’s stock worth $191,000 after buying an additional 4,560 shares during the period. Vanguard Group Inc. increased its position in Curis by 6.7% during the first quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock worth $13,421,000 after buying an additional 304,268 shares during the period. Geode Capital Management LLC increased its position in Curis by 8.3% during the first quarter. Geode Capital Management LLC now owns 918,592 shares of the biotechnology company’s stock worth $2,553,000 after buying an additional 70,139 shares during the period. Finally, Bank of America Corp DE increased its position in Curis by 58.7% during the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the period. 46.88% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Curis, Inc. (CRIS) Stock Price Down 5.4%” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/20/curis-inc-cris-stock-price-down-5-4.html.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Stock Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related stocks with our FREE daily email newsletter.